— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk — Aug. 17, 2026 -- OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced dosing of the first patient following the clearance of the Investigational New Drug (IND) application for a

argenx said Monday the subcutaneous (SC) version of its human IgG1 antibody fragment Vyvgart (efgartigimod alfa), marketed as Vyvgart Hytrulo, cleared a Phase III trial in adults with autoimmune myositis. "For decades, people living with autoimmune myositis have relied on corticosteroids and broad immunosuppression," said Luc Truyen, chief medical officer of argenx, noting that "precision targeting of FcRn with [Vyvgart] can deliver meaningful benefit in this disease." The late-stage portion o

Aizen Therapeutics inked a multi-programme collaboration with an undisclosed, publicly listed San Diego-based biotech to design oral peptide therapeutics. The deal, announced over the weekend, grants Aizen several million in initial revenue, alongside milestone payments of up to $100 million for each chosen target. The latest partnership will employ Aizen's DaX foundation model to develop oral peptides targeting conditions across immunology and neurology. According to the AI-native firm, DaX —

Otsuka Pharmaceuticals’ Voyxact is not the only IgA nephropathy drug that can slow the decline of kidney function. Vera Therapeutics’ Trutakna, which the FDA granted accelerated approval last month, showed “impressive” stabilization, analysts say. In June, Otsuka Pharmaceuticals touted data suggesting its IgA nephropathy drug Voyxact could slow the decline of kidney function in patients—a unique benefit, analysts said at the time. Now, Vera Therapeutics seems to have taken that distinguishing a

Multi-program deal with revenue potential of $100 million per target Aug. 15, 2026 -- Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, today announced a multi-program collaboration with a San Diego-based, public biotech to design oral peptide therapeutics using its DaX™ foundation model. The agreement provides Aizen with several million dollars in initial revenue and up to $100 million in milestones for each nominated target. "Oral biologics represent

After its last attempt at a merger failed in 2023, Redx Pharma seems to have found a willing partner in Skye Bioscience, which experienced a couple of trial failures in recent years. The public biotech has entered into an agreement to combine with privately held fibrotic disease company Redx in a deal that will net $125 million in financing for a new public company called Fibrx Therapeutics. The deal mirrors the structure of a reverse merger. The combined firm will be led by Redx’s current lead

Bayer has announced that the National Medical Products Administration (NMPA) in China has accepted for review the application for aflibercept 8 mg (114.3 mg/ml solution for injection) to treat patients with visual impairment due to macular edema following Retinal Vein Occlusion (RVO) including central, branch, and hemiretinal vein occlusion. Macular edema following RVO is a significant cause of visual impairment worldwide, including in China, and can result in sudden and rapid vision loss. Dr.

Remepy has closed a $36m Series A financing round to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug pipeline. The proceeds will also be used to fund Remepy’s lead product Hybridopa’s global Phase III clinical trial targeting Parkinson’s disease (PD). It is set to commence in the fourth quarter of 2026. The latest funding brings the total capital raised by the company to $62m. The Series A round was led by OG Venture Partners and M Ventures, Merck KGaA, Da

The US Food and Drug Administration (FDA) has granted priority review designation for the new drug application for tinlarebant (LBS-008; Belite Bio) for the treatment of Stargardt Disease Type 1 (STGD1). The FDA has set a Prescription Drug User Fee Act date of February 12, 2027. According to the company, the filing was based on the results from the phase 3 DRAGON trial, which evaluated tinlarebant for the treatment of STGD1. In the study, tinlarebant demonstrated a statistically significant and

China-based IASO Biotechnology has completed the acquisition of MediSix Therapeutics, a Singapore-based immune cell engineering company, adding a proprietary T-cell fratricide-prevention platform and a Phase I clinical asset targeting CD7-positive T-cell malignancies to its existing CAR-T portfolio. The deal extends IASO Bio's cell therapy footprint beyond its approved anti-BCMA product into hematologic indications where conventional CAR-T approaches have been technically constrained. Financial